| Contributors: |
Chioncel, O.; Savarese, G.; Laroche, C.; Amir, O.; Tokmakova, M.; Cannata, A.; Do Doan, L.; Kafafy, T. A. N. A.; Krejci, J.; Moura, B.; Lund, L.; Adamo, M.; Guillouche, W.; Volterani, M.; Iung, B.; Metra, M.; Volterrani, M.; Abir-Khalil, S.; Abu-Hantash, H.; Kafafy, T. A.; Alali, J.; Antohi, E.; Bekbossynova, M.; Bosevski, M.; Christodoulides, T.; Dankova, M.; Dupont, M.; Elmet, M.; Erglis, A.; Gellen, B.; Glavas, D.; Grupper, A.; Gurung, M.; Ibrahimi, P.; Martins, E.; Mirrakhimov, E.; Pallangyo, P.; Pawlak, A.; Perrone-Filardi, P.; Polovina, M.; Mayoral, A. R.; Sarnighausen, H.; Sisakian, H.; Ulziisaikhan, G.; Uzeyir, R.; Wong, R.; Yildirimturk, O.; Zaliaduonyte, D.; Kartoyan, Z.; Danoyan, A.; Ghukasyan, A.; Hayrapetyan, L.; Makaryan, Y.; Martirosyan, S.; Hayrapetyan, H.; Avoyan, H.; Tavaratsyan, A.; Muradyan, N.; Shahnazaryan, S.; Stamboltsyan, M.; Najafov, R.; Agayeva, T.; Babayeva, N.; Gasimov, Z.; Isayeva, M.; Pashayeva, M.; Quliyeva, A.; Karimli, E.; Abdulalimova, K.; Mustafaeva, S.; Suleymanli, L.; Temishova, J.; Aliyev, F.; Rahimli, V.; Imanov, G.; Eyyubov, G.; Aghamaliyev, M.; Alasgarova, N.; Hasilov, E.; Huseynova, S.; Mirzoyev, U.; Alasgarli, S.; Gulay, M.; Karimkhanov, A. |
| Description: |
Heart failure (HF) is characterized by increasing prevalence, high morbidity and mortality, poor quality of life, and substantial healthcare costs. Despite advancements in pharmacologic and device-based therapies, translating evidence from randomized controlled trials into clinical practice remains suboptimal. The Global Registries and Surveys Programme–Heart Failure (GRASP-HF) is a pan-European, snapshot, observational study, aiming at assessing the real-world implementation of evidence-based HF management. GRASP-HF captures both acute and chronic HF presentations to assess the adherence to the 2021 and 2023 European Society of Cardiology (ESC) HF Guidelines. It also serves as a platform for the accreditation of HF centres for the Improving Care through Accreditation and Recognition in Heart Failure (ICARe-HF) programme. This manuscript outlines the rationale, methodology, and design of GRASP-HF. Unlike previous registries, GRASP-HF ensures that all patients are consecutively enrolled over a pre-defined 2-month period, minimizing selection bias. GRASP-HF offers a real-time perspective on diagnostic strategies, use of guideline-recommended medical therapy and implementation of quality-of-care indicators. In addition, GRASP-HF addresses less explored domains by other registries, such as frailty, rare aetiologies (e.g. amyloidosis, genetic cardiomyopathies, Takotsubo syndrome), as well as non-fatal events during hospitalization and follow-up. GRASP-HF is also designed to inform ESC educational strategies and to benchmark progresses in HF care across European and non-European centres. In conjunction with ICARe-HF, annual repetition of GRASP-HF aims to facilitate continuous feedback between evidence, practice, and quality improvement. GRASP-HF will assist National Cardiac Societies in shaping national and institutional policies and will contribute with data-driven insights to future guideline development. |